UJ BIOMED CO., LTD.
Update：2026/09/15
Industries
Main Industry
Biotechnology
Main Product/Service
1. Circulating Tumor Cell (CTC) Detection: Non-invasive, advanced, precise, and real-time liquid biopsy testing
2. Immune Cell Testing: Cancer immunotherapy and autoimmune therapy evaluation
(The content above was translated by AI.)
2. Immune Cell Testing: Cancer immunotherapy and autoimmune therapy evaluation
(The content above was translated by AI.)
Founded Year
2015
Unified Business No.
42613473
Status
Active
Number of Employees
0
Total Paid-in
Capital
38,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
UJ BIOMED CO., LTD. was established in June 2015. It primarily connects basic medical research with clinical practice through translational medicine, providing testing services to domestic medical institutions (laboratories) and health examination centers. Currently, peripheral blood cell testing is its primary service, while it also undertakes commissioned projects from industry, government, and academia. Based on its existing immune cell (system) function testing, its primary goal is to develop advanced medical laboratory testing. It develops peripheral blood rare cell testing, including rare cancer cells, fetal cells, and stem cells in peripheral blood. Currently, the testing services provided mainly focus on "circulating tumor cell testing" and "immune cell testing" as the primary service items.
In October 2015, the company entered the incubator center of a teaching hospital, integrating the spirit of CLIA (Clinical Laboratory Improvement Amendments) regulations into its medical testing service model to align with clinical applications. In addition, it is actively establishing preparations for cancer immunotherapy-related treatments in Taiwan. Through collaboration with physicians from medical centers, teaching or regional hospitals, and specialized clinics, professional medical technologists and experienced clinicians interpret the results to ensure that every customer receives the best testing information, establishing a brand-new testing and business model in Taiwan. It is hoped that the new testing services can provide real-time and effective information, benefiting patients and improving the quality of healthcare for the public.
(The content above was translated by AI.)
In October 2015, the company entered the incubator center of a teaching hospital, integrating the spirit of CLIA (Clinical Laboratory Improvement Amendments) regulations into its medical testing service model to align with clinical applications. In addition, it is actively establishing preparations for cancer immunotherapy-related treatments in Taiwan. Through collaboration with physicians from medical centers, teaching or regional hospitals, and specialized clinics, professional medical technologists and experienced clinicians interpret the results to ensure that every customer receives the best testing information, establishing a brand-new testing and business model in Taiwan. It is hoped that the new testing services can provide real-time and effective information, benefiting patients and improving the quality of healthcare for the public.
(The content above was translated by AI.)
